Equities

Xiamen Amoytop Biotech Co Ltd

688278:SHH

Xiamen Amoytop Biotech Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)58.80
  • Today's Change-2.26 / -3.70%
  • Shares traded1.50m
  • 1 Year change+77.43%
  • Beta0.7297
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments670572481
Total Receivables, Net460243229
Total Inventory187130116
Prepaid expenses23117.40
Other current assets, total0.310.010.51
Total current assets1,340956834
Property, plant & equipment, net542408238
Goodwill, net------
Intangibles, net353342310
Long term investments37----
Note receivable - long term------
Other long term assets0.410.521.08
Total assets2,3561,7701,424
LIABILITIES
Accounts payable419739
Accrued expenses24411376
Notes payable/short-term debt0010.00
Current portion long-term debt/capital leases4.164.185.79
Other current liabilities, total1155346
Total current liabilities404268177
Total long term debt3.765.569.37
Total debt7.929.7425
Deferred income tax0.41155.54
Minority interest------
Other liabilities, total727471
Total liabilities480362263
SHAREHOLDERS EQUITY
Common stock407407407
Additional paid-in capital397397397
Retained earnings (accumulated deficit)1,073604357
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,8761,4081,161
Total liabilities & shareholders' equity2,3561,7701,424
Total common shares outstanding407407407
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.